Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVE0010 versus exenatide on top of metformin in type 2 diabetes
2007-005883-28Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Primary HbA1c change. Started Apr 2008; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-005883-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005883-28.